^
Association details:
| Biomarker: | ARID1A mutation+ KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prevalence and association of ARID1A with driver alterations and immune checkpoint inhibitor (ICPi) biomarkers in cell-free circulating tumor DNA (ctDNA) from 27,000 non-small cell lung cancer (NSCLC) patients.
Published date:
05/13/2020
Excerpt:
Activating KRAS mutations were significantly more frequent in patients with fARID1A (31.1% vs 19.4%; p < 0.0001), including KRAS G12C (10.9% vs 7.0%; p < 0.0001)....The frequency of STK11 mutations, a possible negative predictor of ICPi efficacy, was not significantly different. KRAS mutations were significantly more frequent in patients with fARID1A, notable given recent data reporting that KRAS mutations, particularly KRAS G12C, may be a positive predictor of ICPi response in NSCLC.
DOI:
10.1200/JCO.2020.38.15_suppl.9523
